Results 141 to 150 of about 12,305,089 (195)
Some of the next articles are maybe not open access.
Synthesis of Lipid A Derivatives and Their Interactions with Polymyxin B and Polymyxin B Nonapeptide
Journal of the American Chemical Society, 2003Lipid A is the causative agent of Gram-negative sepsis, a leading cause of mortality among hospitalized patients. Compounds that bind lipid A can limit its detrimental effects. Polymyxin B, a cationic peptide antibiotic, is one of the simplest molecules capable of selectively binding lipid A and may serve as a model for further development of lipid A ...
Ning, Yin +3 more
openaire +2 more sources
Archives of Dermatology, 1963
To the Editor : In the June, 1961, issue of theArchives of Dermatology, G. Asboe-Hansen, M.D., Copenhagen, Denmark, reported the therapeutical essay of polymyxin B (Pfizer) in a case of generalized mastocytosis. We tried this treatment, utilizing disyncran as a cover against histamine liberation, in a case of urticaria pigmentosa which had resisted ...
openaire +3 more sources
To the Editor : In the June, 1961, issue of theArchives of Dermatology, G. Asboe-Hansen, M.D., Copenhagen, Denmark, reported the therapeutical essay of polymyxin B (Pfizer) in a case of generalized mastocytosis. We tried this treatment, utilizing disyncran as a cover against histamine liberation, in a case of urticaria pigmentosa which had resisted ...
openaire +3 more sources
New England Journal of Medicine, 1964
GRAM-negative bacilli, in particular pseudomonas species, are of increasing concern to the clinician as infectious and therapeutic problems.1 , 2 Accordingly, polymyxin B has grown to singular importance as its utility to the treatment of systemic infections caused by pseudomonas species has been appreciated and exploited.
N M, NORD, P D, HOEPRICH
openaire +2 more sources
GRAM-negative bacilli, in particular pseudomonas species, are of increasing concern to the clinician as infectious and therapeutic problems.1 , 2 Accordingly, polymyxin B has grown to singular importance as its utility to the treatment of systemic infections caused by pseudomonas species has been appreciated and exploited.
N M, NORD, P D, HOEPRICH
openaire +2 more sources
Population Pharmacokinetics of Polymyxin B
Clinical Pharmacology & Therapeutics, 2018Polymyxin B is used as a last treatment resort for multidrug‐resistant Gram‐negative bacterial infections. The objectives of this study were to examine the population pharmacokinetics of polymyxin B and investigate factor(s) influencing pharmacokinetic variability.
Pooja, Manchandani +6 more
openaire +2 more sources
Polymyxin-B-binding sites in the cochlea as demonstrated by polymyxin-B/gold labeling
Histochemistry, 1986A polymyxin-B/bovine-serum-albumin/gold complex was used as a probe to detect the binding sites of polymyxin B on thin sections of cochlea embedded in Spurr's resin. The binding sites were found to be mainly located on the stereocilia, the cuticular plate of hair cells, the head plate of Deiters' cells, the tonofilaments in pillar cells and Deiters ...
M, Tachibana +3 more
openaire +2 more sources
Polymyxin B: similarities to and differences from colistin (polymyxin E)
Expert Review of Anti-infective Therapy, 2007Hospital-acquired infections due to multidrug-resistant gram-negative bacteria constitute major health problems, since the medical community is continuously running out of available effective antibiotics and no new agents are in the pipeline. Polymyxins, a group of antibacterials that were discovered during the late 1940s, represent some of the last ...
Andrea, Kwa +3 more
openaire +2 more sources
Prolonged Treatment with Polymyxin B
New England Journal of Medicine, 1960BECAUSE polymyxin B has significant toxic potentialities its use is sharply circumscribed, and prolonged therapy with it is avoided. This report describes an unusual case in which circumstances necessitated the administration of polymyxin B for almost one year to a patient with a single functioning kidney.
openaire +2 more sources
2019
Polymyxin B is another clinically available polymyxin that has re-emerged in clinical practice to treat infections caused by multi-drug (MDR) or extensively-drug-resistant (XDR) Gram-negative bacteria (GNB). Its chemical structure is very similar to the structure of polymyxin E (colistin).
Maria Helena, Rigatto +2 more
openaire +2 more sources
Polymyxin B is another clinically available polymyxin that has re-emerged in clinical practice to treat infections caused by multi-drug (MDR) or extensively-drug-resistant (XDR) Gram-negative bacteria (GNB). Its chemical structure is very similar to the structure of polymyxin E (colistin).
Maria Helena, Rigatto +2 more
openaire +2 more sources
Studies of the biosynthesis of polymyxin B
Biochimica et Biophysica Acta (BBA) - General Subjects, 1968Abstract Polymyxin B, a polypeptide antibiotic produced by Bacillus polymyxa, is synthesized towards the end of the exponential growth phase of the organism. Radioactive diaminobutyric acid is taken up by the cells and incorporated into the antibiotic and into other basic peptides.
openaire +2 more sources
Peptide Antibiotics (Polymyxin B and Polymyxin E)
1978Of the five polymyxins, A, B, C, D and E, originally isolated from a spore-bearing bacillus called variously B. aerosporus and B. polymyxa (Garrod et al., 1973), only two have found clinical usefulness, namely polymyxin B, usually in the form of the sulphate, and polymyxin E (colistin), either as the sulphate or sodium sulphomethate.
A. P. Ball, J. A. Gray, J. McM. Murdoch
openaire +1 more source